Phase 3 Head and Neck Cancer Trial, Recruiting NCT04333537 Sponsor: NRG Oncology Condition: Head and Neck Cancer
Back to Head And Neck Cancer

Phase 3 Head and Neck Cancer Trial, Recruiting

NCT04333537
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed (confirmed by tissue or cell testing) with squamous cell carcinoma (a type of cancer) in the mouth area — this includes the tongue, floor of the mouth, inner lip, inner cheek, lower or upper gum ridge, the area behind the back molars, or the roof of the mouth
  • People whose cancer is at an early stage (T1 or T2, with no spread to lymph nodes or distant parts of the body, based on standard staging guidelines), confirmed by a physical examination and head/neck and chest imaging done within the past 42 days
  • People who a surgeon has assessed as suitable for a specific type of surgery involving removal of the main tumour through the mouth and a lymph node procedure in the neck, all done within the past 42 days
  • People aged 18 or older
  • People with a general health and activity level that falls within an acceptable range (confirmed by assessment within the past 42 days)
  • Women who could become pregnant must have had a negative pregnancy test (blood or urine) within the past 42 days
  • People who are able to read and understand English or French (required because a key questionnaire used in this trial is only available in those two languages)
  • People who have completed a specific quality-of-life questionnaire (called the NDII) before moving to the next stage of the trial
  • People whose PET/CT scan (a type of imaging scan done before the second stage of the trial) shows no cancer in the lymph nodes, as confirmed by a central review team
  • People (or their legal representative) who have given written consent to participate in the study

Who may not be able to join:

  • People whose cancer has already clearly spread to lymph nodes in the neck or to other parts of the body
  • People who have had another type of invasive cancer (not counting certain treated skin cancers or early-stage breast or cervical conditions) unless they have been cancer-free for at least 2 years
  • People whose squamous cell carcinoma is located in other parts of the throat or voice box area (such as the oropharynx, nasopharynx, hypopharynx, or larynx) rather than the mouth
  • People who are unwilling or unable to complete the required questionnaire
  • People who have previously received chemotherapy specifically for this mouth cancer (prior chemotherapy for a different cancer may be acceptable — confirm with trial site)
  • People who have had radiation therapy to the same area of the body in a way that would overlap with any future radiation treatment
  • People with serious ongoing health conditions that would make neck surgery too risky
  • People who are pregnant or breastfeeding
  • People whose mouth cancer was not fully removed, leaving a positive (cancerous) margin after surgery — though a prior biopsy-style removal is acceptable
  • People who have had prior surgery to the side of the neck (such as a previous neck dissection or a serious neck injury that would prevent further surgery in that area) — prior thyroid surgery or a simple biopsy may be acceptable (confirm with trial site)
  • People with a known history of blood cancers (such as certain types of leukaemia) or other active conditions known to cause enlarged lymph nodes (such as sarcoidosis or untreated tuberculosis-type infections)
  • People currently receiving chemotherapy, immunosuppressive medicines, or other treatments that affect the immune system
  • People currently taking part in another clinical trial involving an experimental treatment

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 16 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
NRG Oncology
Registry
ClinicalTrials.gov
Start date
23 September 2020
Est. completion
27 April 2031

Where this trial is recruiting

🇨🇦 Canada 🇺🇸 United States

Primary endpoints

Patient-reported neck and shoulder function (Phase II/III); Patient reported quality of life (QOL) (Phase II); Disease-free survival (DFS) (phase III)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov